ClinicalTrials.gg
Not yet recruitingNCT07519681Updated May 11, 2026

Effects of Berberine on the Human Gut Microbiome

An interventional study of Berberine Hydrochloride in Colorectal Adenomas and Colorectal Cancers, sponsored by Jing-yuan Fang, MD, Ph. D. Not yet recruiting. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Jing-yuan Fang, MD, Ph. D · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Berberine hydrochloride is a conventional component in Chinese medicine. In recent years, anticancer activity of berberine hydrochloride have been explored. The aim of this study is to investigate the effect of berberine hydrochloride on the human gut microbiome.

02

Conditions studied

  • Colorectal Adenomas
  • Colorectal Cancers

Keywords

  • colorectal adenomas
  • colorectal cancers
  • Berberine hydrochloride
  • human gut microbiome
03

In context

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

This study's planned enrollment of 20 is below the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.

Browse Colorectal Neoplasms studies →

Lead sponsor

Jing-yuan Fang, MD, Ph. D is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Outpatients undergoing colonoscopy at Renji Hospital who meet the following criteria:

  1. Aged 18-75 years;
  2. Had at least one but no more than six confirmed colorectal adenomas (including tubular, tubulovillous, and villous adenomas) removed within 6 months prior to enrollment;
  3. Provide for this study and are able to comply with the requirements for collecting qualified stool specimens, peripheral blood specimens, and providing relevant lifestyle and medical history information.

Healthy subjects who meet the following criteria:

  1. Aged 18-75 years;
  2. Have undergone colonoscopy within 6 months prior to enrollment with no histologically confirmed colorectal adenomas (including tubular, tubulovillous, and villous adenomas);
  3. Provide informed consent for this study and are able to comply with the requirements for collecting qualified stool specimens, peripheral blood specimens, and providing relevant lifestyle and medical history information.

Exclusion criteria

Exclusion Criteria:

The following outpatients undergoing colonoscopy at Renji Hospital:

  1. Incomplete resection of adenoma during colonoscopy;
  2. Individuals at high risk for hereditary colorectal cancer;
  3. Regular use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), COX-2 inhibitors, calcium, or vitamin D (defined as daily intake of ≥100 mg aspirin and ≥1200 mg calcium for at least 3 months);
  4. History of subtotal gastrectomy, total gastrectomy, or partial enterectomy;
  5. History of severe cardiac, hepatic, renal disease, or cancer;
  6. Severe constipation or psychiatric disorders;
  7. Pregnant, breastfeeding, or planning to become pregnant;
  8. Undergone colonoscopy with inadequate bowel preparation (rated as "poor" or "insufficient" according to the Aronchik scale) or short observation time (withdrawal time \<6 minutes).
  9. Use of antibiotics, probiotics, or prebiotics within 1 month prior to enrollment.

The following healthy subjects:

  1. Individuals at high risk for hereditary colorectal cancer;
  2. Regular use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), COX-2 inhibitors, calcium, or vitamin D (defined as daily intake of ≥100 mg aspirin and ≥1200 mg calcium for at least 3 months);
  3. History of subtotal gastrectomy, total gastrectomy, or partial enterectomy;
  4. History of severe cardiac, hepatic, renal disease, or cancer;
  5. Severe constipation or psychiatric disorders;
  6. Pregnant, breastfeeding, or planning to become pregnant;
  7. Undergone colonoscopy with inadequate bowel preparation (rated as "poor" or "insufficient" according to the Aronchik scale) or short observation time (withdrawal time \<6 minutes).
  8. Use of antibiotics, probiotics, or prebiotics within 1 month prior to enrollment.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Berberine hydrochloride administration

    Drug: Berberine Hydrochloride

Interventions

06

What researchers measure

Primary outcomes

  1. Relative abundance of Akkermansia in fecal samples as measured by quantitative PCR (qPCR)

    Fecal samples will be collected at baseline (prior to berberine hydrochloride administration) and after treatment. The relative abundance of Akkermansia will be quantified using quantitative PCR (qPCR) targeting species-specific 16S rRNA gene sequences. Results will be expressed as the relative abundance normalized to total bacterial load (ΔCt method). Changes from baseline to post-treatment will be calculated for each participant and summarized across the study population.

    Time frame: 2 weeks

Secondary outcomes

  1. Relative abundance and diversity of gut microbiota in fecal samples as assessed by 16S rRNA gene sequencing

    Fecal samples will be collected at baseline (prior to berberine hydrochloride administration) and after treatment. Gut microbiota composition will be analyzed using 16S rRNA gene sequencing. Outcomes will include: 1. relative abundance of bacterial taxa at the phylum and genus levels (excluding Akkermansia where applicable), and 2. alpha diversity indices (Shannon index). Changes from baseline to post-treatment will be calculated for each participant and summarized across the study population.

    Time frame: 2 weeks

  2. Plasma concentration of indole-3-pyruvic acid (IPyA) as measured before and after berberine hydrochloride administration

    Peripheral blood samples will be collected at baseline (prior to berberine hydrochloride administration) and after treatment. The concentration of indole-3-pyruvic acid (IPyA) in plasma will be quantified using a validated analytical method (liquid chromatography-mass spectrometry, LC-MS). Changes in IPyA concentration from baseline to post-administration will be calculated for each participant and summarized across the study population.

    Time frame: 2 weeks

  3. Fecal concentration of indole-3-pyruvic acid (IPyA) as measured before and after berberine hydrochloride administration

    Fecal samples will be collected at baseline (prior to berberine hydrochloride administration) and after treatment. The concentration of indole-3-pyruvic acid (IPyA) in fecal samples will be quantified using a validated analytical method (liquid chromatography-mass spectrometry, LC-MS). Changes in IPyA concentration from baseline to post-administration will be calculated for each participant and summarized across the study population.

    Time frame: 2 weeks

  4. Number of participants with abnormal liver and renal function laboratory values

    Blood samples will be collected at baseline (prior to berberine hydrochloride administration) and after treatment. Liver function will be assessed by serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil), and albumin. Renal function will be evaluated using serum creatinine (Cr) and blood urea nitrogen (BUN). Abnormal laboratory values will be defined according to institutional reference ranges. The number and proportion of participants with abnormal values after treatment will be reported. Changes from baseline for each parameter will also be summarized descriptively.

    Time frame: 2 weeks

  5. Proportion of VEGFA-positive cells in adenoma tissue as assessed by immunohistochemistry

    Adenoma tissue samples will be obtained at the time of endoscopic resection for patients with colorectal adenomas, before and after administration of hydrochloride berberine. Immunohistochemical staining will be performed to detect vascular endothelial growth factor A (VEGFA) expression. The proportion of VEGFA-positive cells will be quantified by calculating the percentage of positively stained cells among total cells in representative high-power fields. Results will be summarized descriptively across participants. If applicable, comparisons with baseline or between subgroups may be explored.

    Time frame: Baseline and at follow-up colonoscopy (approximately 6 months [±2 months] after treatment)

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Sep 2026, 4 months later.

Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's planned 4 months is below that.

Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2026
First posted
Apr 9, 2026
StartEst.
May 15, 2026
Primary completionEst.
Sep 15, 2026
CompletionEst.
Oct 15, 2026
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07519681
Lead sponsor
Jing-yuan Fang, MD, Ph. D
Responsible party
Jing-yuan Fang, MD, Ph. D (Professor Dr. Jing-yuan Fang, Shanghai Jiao Tong University School of Medicine) — Sponsor-investigator
First posted
Apr 9, 2026
Start date
May 15, 2026 (estimated)
Primary completion
Sep 15, 2026 (estimated)
Completion
Oct 15, 2026 (estimated)
Last update
May 11, 2026

Study contacts

Ziran Kang, M.D.
Contact
renekang@foxmail.com
(86)18826429521
Jingyuan Fang, M.D.
principal investigator · Division of Gastroenterology and Hepatology, NHC Key Laboratory of Digestive Diseases, Renji Hospital, School of Medicine, Shanghai Jiao Tong University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Berberine hydrochloride

Start the discussion